{
    "id": 2600,
    "name": "laryngeal carcinoma",
    "source": "DOID",
    "definition": "A larynx cancer that has_material_basis_in epithelial cells. [url:http\\://en.wikipedia.org/wiki/Carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:2600",
    "evidence": [
        {
            "id": 4295,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ME22S inhibited cell migration, invasion, and proliferation of human laryngeal carcinoma cell lines in culture and inhibited tumor growth in laryngeal carcinoma xenograft models (PMID: 26812910).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3479,
                "therapyName": "ME22S",
                "synonyms": null
            },
            "indication": {
                "id": 2600,
                "name": "laryngeal carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4488,
                    "pubMedId": 26812910,
                    "title": "The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26812910"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        
    ]
}